利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.009 秒)

    DEVICES FOR ADMINISTERING ELECTRICAL STIMULATION TO TREAT CANCER
    10.
    发明公开
    DEVICES FOR ADMINISTERING ELECTRICAL STIMULATION TO TREAT CANCER 审中-实审

    公开(公告)号：EP4397361A3

    公开(公告)日：2024-08-28

    申请号：EP24171875.8

    申请日：2020-04-16

    申请人： Boston Scientific Scimed, Inc.

    发明人： SCHMIDT, Brian L. ,  STEIN, Benjamin Keitz ,  MAILE, Keith R. ,  LINDER, William J. ,  BALCZEWSKI, Ron A. ,  GRUBA, Sarah Melissa ,  NELSON, Tucker James ,  KHARAM, Aleksandra

    IPC分类号： A61N1/36 ,  A61N1/40 ,  A61N1/04

    CPC分类号： A61N1/36002 ,  A61N1/3614 ,  A61N1/40 ,  A61N1/0476 ,  A61N1/403

    摘要： The present invention relates to a medical device for treating a cancerous tumor comprising: an electric field generating circuit configured to generate one or more electric fields at or near a site of the cancerous tumor; control circuitry in communication with the electric field generating circuit, the control circuitry configured to control delivery of the one or more electric fields from the electric field generating circuit; wherein the control circuitry causes the electric field generating circuit to generate one or more electric fields having a field strength selected from a range of from 0.25 V/cm to 1000 V/cm; one or more supply wires in electrical communication with the electric field generating circuit, the one or more supply wires each in electrical communication with one or more supply electrodes, wherein one or more supply electrodes are configured to deliver an electric field at or near the site of the cancerous tumor; and one or more sensing wires in electrical communication with the control circuitry, the one or more sensing wires each in electrical communication with one or more sensing electrodes; and wherein the one or more sensing electrodes are configured to measure an impedance of the cancerous tumor at least two different electric field strengths; and wherein the control circuitry is configured to modulate the one or more electric fields if the impedance at or near the site of the cancerous tumor changes by at least 5 % during a therapy relative to an initial impedance at or near the site of the cancerous tumor at a beginning of the given therapy.